Alembic Pharmaceuticals Limited has informed the stock exchanges that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) and communicated the closure of inspection for the company's Bioequivalence Facility located at Vadodara, Gujarat.
The inspection was conducted by USFDA from 3rd March, 2025 to 7th March, 2025. This update references the company's previous intimation dated 7th March, 2025 regarding the completion of the USFDA inspection at the same facility.
The communication confirms regulatory compliance closure without any adverse observations mentioned in the disclosure. The filing serves as a formal regulatory compliance update to the stock exchanges.